ArticleSAGE open medical case reports2025
Anti-PD-1-induced bullous pemphigoid in a renal transplant recipient.
Article in SAGE open medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors, particularly anti-PD-1 agents, are increasingly associated with bullous pemphigoid, a rare yet significant immune-related adverse event. We report a case of immune checkpoint inhibitor-induced bullous pemphigoid in a 74-year-old renal transplant recipient undergoing cemiplimab and later pembrolizumab for recurrent cutaneous squamous cell carcinomas. Bullous pemphigoid developed 23 months after initial immune checkpoint inhibitor exposure and 4 weeks after pembrolizumab reinitiation, presenting with generalized pruritus and tense bullae. Diagnosis was confirmed by histology and direct immunofluorescence. Disease was managed with oral prednisone and topical steroids, with relapses occurring upon tapering. This case highlights the complex interplay between immune checkpoint inhibitors, transplant immunosuppression, and autoimmune toxicity, underscoring the need for personalized, multidisciplinary management strategies in transplant patients receiving immune checkpoint inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.